Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.24 Insider Own0.04% Shs Outstand125.30M Perf Week-17.47%
Market Cap171.66M Forward P/E- EPS next Y-0.30 Insider Trans-33.28% Shs Float125.25M Perf Month-15.95%
Income-30.09M PEG- EPS next Q-0.07 Inst Own12.94% Short Float8.43% Perf Quarter67.07%
Sales0.00M P/S- EPS this Y-13.89% Inst Trans-14.05% Short Ratio6.62 Perf Half Y103.26%
Book/sh0.73 P/B1.89 EPS next Y-8.54% ROA-27.38% Short Interest10.56M Perf Year83.99%
Cash/sh0.71 P/C1.94 EPS next 5Y- ROE-28.80% 52W Range0.59 - 2.31 Perf YTD55.68%
Dividend Est.- P/FCF- EPS past 5Y46.61% ROI-33.06% 52W High-40.69% Beta1.30
Dividend TTM- Quick Ratio17.61 Sales past 5Y0.00% Gross Margin- 52W Low132.16% ATR (14)0.20
Dividend Ex-Date- Current Ratio17.61 EPS Y/Y TTM-12.07% Oper. Margin0.00% RSI (14)41.89 Volatility12.68% 13.80%
Employees12 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price4.00
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-4.56% Payout- Rel Volume0.74 Prev Close1.42
Sales Surprise- EPS Surprise0.00% Sales Q/Q- EarningsApr 01 AMC Avg Volume1.60M Price1.37
SMA20-22.37% SMA500.36% SMA20040.62% Trades Volume1,176,796 Change-3.52%
Date Action Analyst Rating Change Price Target Change
Jan-26-18Initiated Maxim Group Buy $2
Apr-15-24 08:30AM
Apr-11-24 10:10AM
Apr-09-24 11:59AM
Apr-01-24 10:53PM
04:00PM Loading…
Mar-19-24 08:30AM
Mar-18-24 08:30AM
Mar-12-24 08:30AM
Mar-06-24 08:30AM
Feb-22-24 08:30AM
Feb-07-24 08:30AM
Jan-09-24 08:30AM
Dec-18-23 09:00AM
Dec-08-23 09:40AM
08:30AM Loading…
Dec-04-23 08:30AM
Nov-20-23 08:30AM
Nov-13-23 09:00AM
Nov-09-23 09:00AM
Oct-30-23 01:00PM
Oct-11-23 08:30AM
Sep-18-23 09:25AM
Aug-23-23 08:00AM
Aug-14-23 08:30AM
Aug-08-23 09:00AM
Jul-20-23 09:15AM
Jul-13-23 04:15PM
Jul-12-23 09:00AM
Jul-10-23 09:15AM
09:28PM Loading…
Jul-06-23 09:28PM
Jun-28-23 01:03PM
Jun-27-23 09:15AM
Jun-22-23 04:15PM
Jun-21-23 01:48PM
Jun-14-23 09:15AM
Jun-12-23 09:15AM
Jun-01-23 09:10AM
May-23-23 07:00AM
May-15-23 09:10AM
May-11-23 09:00AM
May-09-23 09:15AM
Apr-27-23 09:15AM
Mar-30-23 11:00AM
Mar-22-23 04:05PM
Mar-21-23 01:19PM
Mar-15-23 09:25AM
Feb-23-23 09:15AM
Feb-13-23 09:15AM
Jan-25-23 09:15AM
Dec-07-22 08:00AM
Nov-07-22 04:00PM
Nov-01-22 09:15AM
Oct-25-22 09:15AM
Oct-24-22 09:15AM
Oct-21-22 10:26AM
Sep-07-22 09:00AM
Aug-22-22 09:30AM
Aug-18-22 09:30AM
Aug-08-22 04:30PM
Jul-28-22 09:00AM
Jul-13-22 06:56PM
Jul-11-22 05:25PM
Jun-02-22 04:05PM
May-18-22 09:30AM
May-14-22 08:55AM
May-09-22 04:05PM
Apr-27-22 09:30AM
Apr-20-22 09:30AM
Mar-23-22 09:30AM
Mar-08-22 09:15AM
Feb-28-22 04:15PM
Feb-07-22 05:30AM
Jan-27-22 09:30AM
Jan-18-22 09:30AM
Dec-22-21 09:30AM
Dec-16-21 09:00AM
Dec-06-21 09:15AM
Dec-05-21 06:38AM
Nov-24-21 09:30AM
Nov-15-21 09:30AM
Oct-21-21 09:30AM
Sep-30-21 09:30AM
Sep-13-21 05:47PM
Sep-10-21 01:48PM
Sep-07-21 05:20PM
Sep-02-21 09:30AM
Aug-25-21 04:11PM
Aug-13-21 09:30AM
Aug-05-21 09:30AM
Jul-15-21 09:00AM
Jul-09-21 10:54AM
Jul-07-21 09:30AM
Jun-16-21 09:00AM
Jun-14-21 06:13PM
Jun-11-21 09:00AM
Jun-09-21 09:00AM
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Finn JonathanDirectorApr 10 '24Buy1.7725,00044,25025,000Apr 11 04:05 PM
WEAVER GREGORY LFormer EVP, CFO, & DirectorNov 15 '23Sale0.6550,00032,50055Nov 17 04:01 PM